10 results on '"Eerenstein, Simone E. J."'
Search Results
2. Cost-Utility of the eHealth Application ‘Oncokompas’, Supporting Incurably Ill Cancer Patients to Self-Manage Their Cancer-Related Symptoms: Results of a Randomized Controlled Trial
- Author
-
Schuit, Anouk S., primary, Holtmaat, Karen, additional, Coupé, Veerle M. H., additional, Eerenstein, Simone E. J., additional, Zijlstra, Josée M., additional, Eeltink, Corien, additional, Becker-Commissaris, Annemarie, additional, van Zuylen, Lia, additional, van Linde, Myra E., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Sommeijer, Dirkje W., additional, Verbeek, Nol, additional, Bosscha, Koop, additional, Nandoe Tewarie, Rishi, additional, Sedee, Robert-Jan, additional, de Bree, Remco, additional, de Graeff, Alexander, additional, de Vos, Filip, additional, Cuijpers, Pim, additional, Verdonck-de Leeuw, Irma M., additional, and Jansen, Femke, additional
- Published
- 2022
- Full Text
- View/download PDF
3. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands
- Author
-
Boon, Eline, Bel, Miranda, van Boxtel, Wim, van der Graaf, Winette T. A., van Es, Robert J. J., Eerenstein, Simone E. J., Baatenburg de Jong, Robert J., van den Brekel, Michiel W. M., van der Velden, Lilly‐Ann, Witjes, Max J. H., Hoeben, Ann, Willems, Stefan M., Bloemena, Elisabeth, Smit, Laura A., Oosting, Sjoukje F., Jonker, Marianne A., Flucke, Uta E., van Herpen, Carla M. L., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Damage and Repair in Cancer Development and Cancer Treatment (DARE), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), MKA AMC (OII, ACTA), MKA Vumc (OII, ACTA), and Otorhinolaryngology and Head and Neck Surgery
- Subjects
Adult ,Male ,DATABASE ,Receptor, ErbB-2 ,receptor ,Receptor, ErbB-2/metabolism ,Receptors, Androgen/metabolism ,THERAPY ,survival ,Disease-Free Survival ,ErbB-2 ,Recurrence ,ErbB‐2 ,Journal Article ,FAILURE ,Humans ,Salivary Ducts ,Neoplasm Metastasis ,Carcinoma/pathology ,salivary duct carcinoma ,Aged ,Netherlands ,Aged, 80 and over ,OUTCOMES ,Carcinoma ,Palliative Care ,ANDROGEN RECEPTOR ,Salivary Ducts/pathology ,Chemoradiotherapy, Adjuvant ,Middle Aged ,Prognosis ,Salivary Gland Neoplasms ,Survival Rate ,androgen receptors ,Receptors, Androgen ,Lymphatic Metastasis ,immunohistochemistry ,Female ,in situ hybridization ,fluorescence ,Factor Analysis, Statistical ,Salivary Gland Neoplasms/pathology ,Cancer Epidemiology - Abstract
Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis and a need for better prognostication and novel treatments. The aim of this national cohort study was to investigate clinical outcome, prognostic factors, androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) expression. SDC patients diagnosed between 1990 and 2014 were identified by the Nationwide Network and Registry of Histo‐ and Cytopathology in the Netherlands (PALGA). Subsequently, medical records were evaluated and pathological diagnoses reviewed. Data were analyzed for overall survival (OS), disease‐free survival (DFS), distant metastasis‐free survival (DMFS) and prognostic factors. AR was evaluated by immunohistochemistry (IHC), HER2 by IHC and fluorescent in‐situ hybridization. A total of 177 patients were included. The median age was 65 years, 75% were male. At diagnosis, 68% presented with lymph node metastases and 6% with distant metastases. Median OS, DFS and DMFS were 51, 23 and 26 months, respectively. In patients presenting without distant metastases, the absolute number of positive lymph nodes was associated with poor OS and DMFS in a multivariable analysis. AR and HER2 were positive in 161/168 (96%) and 44/153 (29%) tumors, respectively, and were not prognostic factors. SDC has a dismal prognosis with primary lymph node involvement in the majority of patients. The absolute number of lymph node metastases was found to be the only prognostic factor for DMFS and OS. AR expression and—to a lesser extent—HER2 expression hold promise for systemic treatment in the metastatic and eventually adjuvant setting., What's new? Salivary duct carcinoma (SDC) is a rare and often fatal malignancy. Little is known about associations between its pathological features and clinical outcome. In this study, clinicopathological factors were analyzed for 177 patients diagnosed with SDC in The Netherlands between 1990 and 2014. The data show that median overall survival (OS) and distant metastasis‐free survival (DMFS) were 51 and 26 months, respectively. At diagnosis, 68% of patients presented with lymph node metastases. Lymph node positivity was associated with poor OS and poor DMFS. The absolute number of metastatic lymph nodes was the only significant prognostic factor for survival in a multivariate analysis. Androgen receptor and human epidermal growth factor 2 (HER2) were positive in 96% and 29%, respectively and were not a prognostic factor.
- Published
- 2018
4. Silver Nitrate Aspiration: A Potentially Life-Threatening Complication
- Author
-
Bekkers, Stijn, primary, Rijken, Johannes A., additional, Daniels, Johannes M. A., additional, Rinkel, Rico N. P. M., additional, Hendrickx, Jan-Jaap, additional, and Eerenstein, Simone E. J., additional
- Published
- 2017
- Full Text
- View/download PDF
5. Effectiveness and cost-utility of a guided self-help exercise program for patients treated with total laryngectomy: protocol of a multi-center randomized controlled trial
- Author
-
Jansen, Femke, primary, Cnossen, Ingrid C., additional, Eerenstein, Simone E. J., additional, Coupé, Veerle M. H., additional, Witte, Birgit I., additional, van Uden-Kraan, Cornelia F., additional, Doornaert, Patricia, additional, Braunius, Weibel W., additional, De Bree, Remco, additional, Hardillo, José A. U., additional, Honings, Jimmie, additional, Halmos, György B., additional, Leemans, C. René, additional, and Verdonck-de Leeuw, Irma M., additional
- Published
- 2016
- Full Text
- View/download PDF
6. A prospective randomized multicenter clinical trial of the Provox2 and Groningen Ultra Low Resistance voice prostheses in the rehabilitation of post-laryngectomy patients: a lifetime and preference study
- Author
-
Harms, Kim, Post, Wendy J., van de Laan, Klaas T., van den Hoogen, Frank J. A., Eerenstein, Simone E. J., van der Laan, Bernard F. A. M., Erenstein, S.E., Otolaryngology / Head & Neck Surgery, CCA - Quality of life, Nieuwenhuis Institute (Pedagogical and Educational Sciences), Faculteit Medische Wetenschappen/UMCG, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Man, Biomaterials and Microbes (MBM)
- Subjects
Male ,medicine.medical_specialty ,Cancer Research ,Patient Dropouts ,CARCINOMA ,TOTAL LARYNGECTOMY ,medicine.medical_treatment ,Groningen Ultra Low Resistance ,Laryngectomy ,Aetiology, screening and detection [ONCOL 5] ,Prosthesis Design ,Prosthesis ,Preference ,Internal medicine ,Surveys and Questionnaires ,Perception and Action [DCN 1] ,medicine ,Humans ,Prospective Studies ,Laryngeal Neoplasms ,RESTORATION ,Netherlands ,Rehabilitation ,business.industry ,Repeated measures design ,Surgery ,Prosthesis Failure ,Clinical trial ,Equipment Failure Analysis ,Oncology ,Patient Satisfaction ,High phonating resistance ,Provox2 ,EXPERIENCE ,Female ,Tracheo-esophageal shunt prosthesis ,Oral Surgery ,Low resistance ,business ,Larynx, Artificial ,Lifetime - Abstract
To prospectively study patients' preference for and the lifetime of the Groningen Ultra Low Resistance (GULR) and Provox2 tracheo-esophageal shunt prosthesis (TESP, plural TESPs) in post-laryngectomy patients. Eighty post-laryngectomy patients were included in 4 oncological centers in the Netherlands. We used a repeated measures design study with 4 randomized groups in a partial cross-over design using 3 consecutive TESPs (3 intervals) in different orders. (Group 1: GULR-GULR-GULR; Group 2: GULR-GULR-Provox2; Group 3: Provox2-Provox2-GULR; and Group 4: Provox2-Provox2-Provox2). Replacement dates and reasons for replacement were monitored with questionnaires as were patients' preferences for GULR or Provox2. A great variability of lifetime within and between groups was seen. Mean lifetimes found (all groups and intervals added) were 106.2 and 102.7 days, and median lifetimes were 76 and 65 days for GULR and Provox2, respectively. Lifetime showed no significant differences between groups, intervals, and TESP types. Many patients dropped out due to reasons having to do with GULR-characteristics (n = 21). The main dropout reason was "high phonating resistance (HPR)" (57.1%). Only 10 patients preferred GULR. A significantly larger number of patients (n = 39, 79.6%) preferred Provox2 either by choice or by dropping out due to GULR-characteristics (P
- Published
- 2011
7. Molecular Detection of Minimal Residual Cancer in Surgical Margins of Head and Neck Cancer Patients
- Author
-
Graveland, A. Peggy, primary, Maaker, Michiel de, additional, Braakhuis, Boudewijn J. M., additional, de Bree, Remco, additional, Eerenstein, Simone E. J., additional, Bloemena, Elisabeth, additional, Leemans, C. René, additional, and Brakenhoff, Ruud H., additional
- Published
- 2009
- Full Text
- View/download PDF
8. Molecular detection of minimal residual cancer in surgical margins of head and neck cancer patients.
- Author
-
Graveland, A. Peggy, de Maaker, Michiel, Braakhuis, Boudewijn J. M., de Bree, Remco, Eerenstein, Simone E. J., Bloemena, Elisabeth, Leemans, C. René, and Brakenhoff, Ruud H.
- Subjects
HEAD & neck cancer ,ONCOLOGIC surgery ,SQUAMOUS cell carcinoma ,POLYMERASE chain reaction - Abstract
A great disappointment in head and neck cancer surgery is that 10–30% of head and neck squamous cell carcinoma (HNSCC) patients develop local recurrences despite histopathologically tumor-free surgical margins. These recurrences result from either minimal residual cancer (MRC) or preneoplastic lesions that remain behind after tumor resection. Distinguishing MRC from preneoplasic lesions is important to tailor postoperative radiotherapy more adequately. Here we investigated the suitability of quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) using human Ly-6D (hLy-6D) transcripts as molecular marker to detect MRC in surgical margins. Submucosal samples of deep surgical margins were collected from 18 non-cancer control patients and 67 HNSCC patients of whom eight had tumor-positive surgical margins. The samples were analyzed with hLy-6D qRT-PCR, and the data were analyzed in relation to the clinicohistological parameters. A significant difference was shown between the group of patients with histopathological tumor-positive surgical margins and the non-cancer control group (p<0.001), and the group of patients with histopathological tumor-free surgical margins (p=0.001). This study shows a novel approach for molecular analysis of deep surgical margins in head and neck cancer surgery. The preliminary data of this approach for detection of MRC in deep margins of HNSCC patients are promising. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
9. Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.
- Author
-
Wondergem NE, Miedema IHC, van de Ven R, Zwezerijnen GJC, de Graaf P, Karagozoglu KH, Hendrickx JJ, Eerenstein SEJ, Bun RJ, Mulder DC, Voortman J, Boellaard R, Windhorst AD, Hagers JP, Peferoen LAN, de Gruijl TD, Bloemena E, Brakenhoff RH, Leemans CR, and Menke-van der Houven van Oordt CW
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology, Molecular Imaging methods, Nivolumab therapeutic use, Nivolumab pharmacology, T-Lymphocytes immunology, T-Lymphocytes metabolism, Programmed Cell Death 1 Receptor antagonists & inhibitors, Positron-Emission Tomography methods, Adult, Mouth Neoplasms drug therapy, Mouth Neoplasms diagnostic imaging, Mouth Neoplasms pathology, Neoadjuvant Therapy methods
- Abstract
Background: Addition of neoadjuvant immune checkpoint inhibition to standard-of-care interventions for locally advanced oral cancer could improve clinical outcome., Methods: In this study, 16 evaluable patients with stage III/IV oral cancer were treated with one dose of 480 mg nivolumab 3 weeks prior to surgery. Primary objectives were safety, feasibility, and suitability of programmed death receptor ligand-1 positron emission tomography (PD-L1 PET) as a biomarker for response. Imaging included
18 F-BMS-986192 (PD-L1) PET and18 F-fluorodeoxyglucose (FDG) PET before and after nivolumab treatment. Secondary objectives included clinical and pathological response, and immune profiling of peripheral blood mononuclear cells (PBMCs) for response prediction. Baseline tumor biopsies and postnivolumab resection specimens were evaluated by histopathology., Results: Grade III or higher adverse events were not observed and treatment was not delayed in relation to nivolumab administration and other study procedures. Six patients (38%) had a pathological response, of whom three (19%) had a major (≥90%) pathological response (MPR). Tumor PD-L1 PET uptake (quantified using standard uptake value) was not statistically different in patients with or without MPR (median 5.3 vs 3.4). All major responders showed a significantly postnivolumab decreased signal on FDG PET. PBMC immune phenotyping showed higher levels of CD8+ T cell activation in MPR patients, evidenced by higher baseline expression levels of PD-1, TIGIT, IFNγ and lower levels of PD-L1., Conclusion: Together these data support that neoadjuvant treatment of advanced-stage oral cancers with nivolumab was safe and induced an MPR in a promising 19% of patients. Response was associated with decreased FDG PET uptake as well as activation status of peripheral T cell populations., Competing Interests: Competing interests: RvdV has received research funding from Genmab BV. TDdG is scientific advisor to Immunicum, GE Health, and Lava Therapeutics, holds stock from LAVA Therapeutics and received research funding from Idera Pharmaceuticals (now Aceragen). RHB received research grants from KWF Kankerbestrijding/Dutch Cancer Society, Cancer Center Amsterdam Foundation, ZonMW and NWO, Genmab BV and the Hanarth Foundation and is on the advisory board of Nanobiotix. He has a scientific collaboration with Orfenix BV and Qialix DoT. CRL received research grants from KWF Kankerbestrijding/Dutch Cancer Society, Cancer Center Amsterdam Foudation, Genmab BV, BMS and the Hanarth Foundation and is on the advisory board of Merck & Co. CWM-vdHvO received research grants from BMS, Boeringher Ingelheim, GSK, Pfizer and AstraZeneca and consulted for GE Health Care, Novartis and EliLilly. All other authors report no competing interests., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2024
- Full Text
- View/download PDF
10. Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial.
- Author
-
Schuit AS, Holtmaat K, Lissenberg-Witte BI, Eerenstein SEJ, Zijlstra JM, Eeltink C, Becker-Commissaris A, van Zuylen L, van Linde ME, Menke-van der Houven van Oordt CW, Sommeijer DW, Verbeek N, Bosscha K, Tewarie RN, Sedee RJ, de Bree R, de Graeff A, de Vos F, Cuijpers P, and Verdonck-de Leeuw IM
- Abstract
Background: Many patients with incurable cancer have symptoms affecting their health-related quality of life. The eHealth application 'Oncokompas' supports patients to take an active role in managing their palliative care needs, to reduce symptoms and improve health-related quality of life (HRQOL). This randomized controlled trial was conducted to determine the efficacy of Oncokompas compared to care as usual among incurably ill cancer patients with a life expectancy of more than three months., Methods: Patients were recruited in six hospitals in the Netherlands. Eligible patients were randomly assigned to the intervention (direct access to Oncokompas) or the control group (access to Oncokompas after three months). The primary outcome measure was patient activation (i.e., patients' knowledge, skills and confidence for self-management). Secondary outcomes were general self-efficacy and HRQOL. Measures were assessed at baseline, two weeks after randomization, and three months after the baseline measurement. Linear mixed models were used to compare longitudinal changes between both groups from baseline to the three-month follow-up., Findings: In total, 219 patients were eligible of which 138 patients completed the baseline questionnaire (response rate 63%), and were randomized to the intervention (69) or control group (69). There were no significant differences between the intervention and control group over time in patient activation (estimated difference in change T0-T2; 1·8 (90% CI: -1·0 to 4·7)), neither in general self-efficacy and HRQOL. Of the patients in the intervention group who activated their account, 74% used Oncokompas as intended. The course of patient activation, general self-efficacy, and HRQOL was not significantly different between patients who used Oncokompas as intended versus those who did not., Interpretation: Among incurably ill cancer patients with a life expectancy of more than three months and recruited in the hospital setting, Oncokompas did not significantly improve patient activation, self-efficacy, or HRQOL., Funding: ZonMw, Netherlands Organization for Health Research and Development (844001105)., Competing Interests: IVdL reports grants from the Netherlands Organization for Health Research and Development (ZonMw), the Dutch Cancer Society (KWF Kankerbestrijding), Bristol Myers Squibb, Danone Ecofund/Nutricia. ABC reports grants from Roche. FdV reports grants from Foundation STOPbraintumors.org and AbbVIe, BMS, Novartis, EORTC, Vaximm and BioClin Therapeutics. FdV reports participation on a DSMB during the conduct of this study, and leaderships or fiduciary roles in other boards and commissions. All other authors declare no competing interests., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.